公开(公告)号：US20240024279A1

公开(公告)日：2024-01-25

申请号：US18131727

申请日：2023-04-06

申请人： INCREVET, INC.

发明人： Michael HADD ,  Brian SEED

IPC分类号： A61K31/351 ,  A61P3/10

CPC分类号： A61K31/351 ,  A61P3/10 ,  A61K9/0053

摘要： Provided herein are methods of reducing the weight loss and/or increasing the weight of a feline in need thereof, said methods include administering to a feline in need thereof a total daily dosage of about 2 to 50 mg of Compound 1, having the formula:




or a pharmaceutically acceptable form thereof. Also provided herein are methods of managing the disease of a feline with diabetes mellitus and elevated IGF-1 concentration.

公开(公告)号：US20230000816A1

公开(公告)日：2023-01-05

申请号：US17775029

申请日：2020-11-06

申请人： INCREVET, INC.

发明人： Michael HADD ,  Brian SEED ,  Thomas John DUPREE ,  Jordan MECHANIC

IPC分类号： A61K31/351 ,  A61K31/4965 ,  A61P13/12 ,  A61P9/04 ,  A61P3/10 ,  A61P9/12

摘要： Provided herein are methods of treating heart failure, chronic kidney disease (CKD) or hypertension, in a companion animal, comprising administering to a companion animal in need thereof a therapeutically effective amount of a compound that inhibits a sodium-dependent glucose transporter (SGLT) or a prodrug thereof. In some embodiments, the compound that inhibits an SGLT is bexagliflozin.

公开(公告)号：US20230372374A1

公开(公告)日：2023-11-23

申请号：US18318133

申请日：2023-05-16

申请人： INCREVET, INC.

发明人： Ning LI ,  Michael J. HADD ,  Brian SEED ,  Gopinath DEVARAJ ,  Esther SEE ,  Su WIN

IPC分类号： A61K31/7034 ,  A61K9/20 ,  A61K47/26 ,  A61K47/10

CPC分类号： A61K31/7034 ,  A61K9/2068 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2009 ,  A61K9/2013 ,  A61K47/26 ,  A61K47/10

摘要： Provided herein are oral immediate release formulations of bexagliflozin for administration to companion animals.

公开(公告)号：US20200289457A1

公开(公告)日：2020-09-17

申请号：US16818026

申请日：2020-03-13

申请人： INCREVET, INC.

发明人： Michael Hadd ,  Albert Collinson ,  Brian Seed

IPC分类号： A61K31/351 ,  A61P3/10

摘要： Provided herein are methods of managing feline diabetes, said methods include administering to a feline in need thereof a total daily dosage of about 5 to 50 mg of Compound 1, having the formula: or a pharmaceutically acceptable form thereof. Also provided herein are methods of managing feline diabetes by administering to a feline in need thereof an effective amount of a SGLT inhibitor, wherein said effective amount is no more than 10 to 30% of the dose required to produce an elevated frequency of diarrhea or loose stool in a healthy feline.